Drug Profile
LX 7101
Alternative Names: LX-7101Latest Information Update: 08 Apr 2016
Price :
$50
*
At a glance
- Originator Lexicon Pharmaceuticals
- Class Antiglaucomas; Small molecules
- Mechanism of Action LIM kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glaucoma; Ocular hypertension
Most Recent Events
- 16 Mar 2016 No development reported - Phase-I/II for Glaucoma in USA (Topical)
- 16 Mar 2016 No development reported - Phase-I/II for Ocular hypertension in USA (Topical)
- 16 Aug 2012 Efficacy and adverse events data from a phase I/IIa trial in Glaucoma or Ocular hypertension released by Lexicon Pharmaceuticals